case 4: egfr mutation analysis post-osimertinib
Published 5 years ago • 341 plays • Length 5:24Download video MP4
Download video MP3
Similar videos
-
6:55
case 4: treating egfr nsclc after osimertinib
-
6:41
case 4: metastatic egfr nsclc progressing on osimertinib
-
3:09
case 2: osimertinib in egfr-mutated lung cancer
-
2:02
case 4: upfront osimertinib in metastatic egfr nsclc
-
3:30
osimertinib for uncommon egfr mutations in nsclc
-
5:18
frontline therapy for egfr plus nsclc: osimertinib’s impact
-
3:31
osimertinib plus gefitinib for treatment of egfr-mutated non-small cell lung cancer
-
3:47
case overview: egfr-positive nsclc
-
2:43
post-osimertinib treatment options for egfr nsclc - targeted therapies in lung cancer 2023
-
1:41
egfr mutations in patients with lung cancer
-
1:13
identification of egfr mutations impact overall prognosis in lung cancers
-
53:55
advancing care for patients with egfr mutation–positive nsclc: precision medicine strategies
-
4:08
case discussion: a 65-year-old man with stage iv nsclc_old2
-
58:24
time for even more precision in testing and treatment of egfr-mutated nsclc
-
5:55
a case of egfr-mutant non–small cell lung cancer
-
4:37
case based panel discussion - egfr mutation treated with tagrisso progression while on treatment, an
-
3:59
osimertinib for egfr t790m resistance mutations in nsclc
-
4:04
treating with osimertinib in egfr-mutated nsclc
-
3:38
osimertinib and plasma genotyping